Shots:

• BMS to acquire all the outstanding shares of MyoKardia’s common stock for $225.00/ share in cash- making a total deal value of ~$13.1B. The transaction is expected to be close in Q4’20
• The acquisition will foster BMS’ CV portfolio with the addition of MyoKardia’s mavacamten. BMS expects to explore mavacamten in additional indications- including non-obstructive HCM and will develop MyoKardia’s two clinical-stage therapies- danicamtiv (formerly MYK-491) and MYK-224
• Mavacamten is a potential first-in-class therapy with compelling data in the treatment of patients with symptomatic obstructive HCM. The NDA submission of the therapy is based on the EXPLORER-HCM study- which is expected to be submitted to the US FDA in the Q1’21

­ Ref: BMS | Image: BMS